Exagen Inc. Announces Select Preliminary 2025 Financial Results

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close: 7.92 USD
Market cap: 116.45M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Related news

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen to Announce Second Quarter Financial Results on August 4, 2026

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

OraSure Announces Second Quarter 2026 Financial Results

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

Exagen